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ABSTRACT
Inducible cAMP early repressor (ICER) is an early response gene that is transcribed from
an intronic promoter of the CREM gene. ICER and other CREM transcripts are expressed
in pineal gland, pituitary gland, sertoli cells, as well as bone and are thought to have a role in
the physiology of circadian rhythms and spermatogenesis. ICER proteins consist of the
DNA binding domains of CREM and act as dominant negative repressors of gene
transcription. Parathyroid hormone induces ICER expression in osteoblastic cells through
the cAMP/PKA pathway. Prostaglandins also work through the cAMP/PKA pathway and
have a myriad of effects on bone metabolism. To determine whether prostaglandins induce
ICER expression in osteoblastic cells, MC3T3-E1 cells and mouse calvariae were treated
with 1 gM PGE2, 1 gM PGF2a and 10 nM PTH. The RNA extracted from these
osteoblastic cells and calvariae was analysed for ICER and osteocalcin expression using
RT-PCR and/or Northern blot analysis. PGE and PGF both induced ICER expression,
but PGFwas a weaker agonist. This induction was maximal at 10 gM PGE2 and 1 gM
PGF. and returned to basal levels by 0.1 nM. ICER expression was also time dependent
with a peak at 2 h that returned to baseline by 10 h. We also studied the relation between
cell differentiation and the expression of ICER by treating MC3T3-E 1 cells with or without
ascorbic acid for up to three weeks. Ascorbic acid was not absolutely necessary for the
differentiation of MC3T3-E1 osteoblastic cells. However, induction of ICER increased as
MC3T3-E1 cells differentiated with ascorbic acid. We conclude that protaglandins Ez and
F induce ICER expression in MC3T3-E1 osteoblastic cells and neonatal mouse calvariae
and this induction is greater as the cells differentiate. ICER may play a role in prostaglandin
mediated gene expression in bone.
INTRODUCTION
Bone
Bone is the integral part of the skeletal system that serves four functions: (i)
mechanical function for soft tissue attachment and movement; (ii) protection for vital
organs; (iii) metabolic function by acting as a reservoir of ions; and (iv) production of blood
cells by hemotopoeisis. The fundamental constituents of bone are the cells and the
extracellular matrix. Bone cells include osteoblasts, osteocytes and osteoclasts (1).
There are two types of bone based on the consistency: cancellous bone, also called
spongy or trabecular bone, and cortical or compact bone, also called medullary bone. The
marrow in cancellous bone consists of thin trabeculae that are filled with hematopoietic bone
marrow. This type of bone fulfills a metabolic function. However, cortical bone is
composed of thick and dense calcified tissue which fulfills the mechanical and protective
function of bone. Cortical bone has two types of surfaces. The inner surface that faces the
bone marrow is called the endosteum. The outer layer that faces the surrounding soft tissue
is called periosteum. The endosteum is in intimate contact with blood vessels and the cells
lining the endosteum are metabolically active and involved in bone remodeling.
Bone is a composite of organic and inorganic matter. Approximately 70% of bone
is mineralized or inorganic matter. The inorganic component of bone is mainly composed
of a calcium phosphate mineral similar to calcium hydroxyapetite. The organic bone matrix
is composed of collagen fibers, mainly type I collagen, osteocalcin, osteonectin,
glycoproteins, proteoglycans, and growth factors. Glycoproteins and proteoglycans are
highly anionic complexes that have a high affinity for ions. Hydroxyapetite crystals are
found on the collagen fibers as well as in the ground substance.
Osteoblasts are bone forming cells that originate from local mesenchymal stem cells
in the bone marrow stromal compartment or connective tissue mesenchymal stem cells (2).
These precursors differentiate into preosteoblasts and then into mature osteoblasts.
Osteoblasts are characterized by their high metabolic activity. This is evident by the
presence of extensive endoplasmic reticulum in the cytoplasm as well as an intricate golgi
apparatus. This feature of osteoblastic cells makes it possible for them to produce a large
amount of collagen that is secreted from the cells. Another characteristic of osteoblastic
cells is the presence of a substantial amount of alkaline phosphatase enzyme, which is
involved in the process of mineralization of the bone matrix. Osteoblasts express receptors
for various hormones such as parathyroid hormone (PTH), estrogens and vitamin D3. As
osteoblasts secrete bone matrix that becomes calcified, they become trapped into the bone
matrix and differentiate into osteocytes. Osteocytes have long cell processes that
communicate with other cells through gap junctions. Osteocytes remain metabolically
active and play a role in activating bone turnover.
Osteoclasts, the major bone resorbing cells, are derived from hematopoietic cells
(3). They are large multinucleated cells that contain 4-20 nuclei depending on the species.
Osteoclasts are characterized by primary lysosomes, abundance of golgi complexes, and
numerous and pleiomorphic mitochondria. The most important feature of the osteoclast is
the presence of folds in the plasma membrane that is in contact with the bone matrix. This
area is called the raffled border and is the site at which resorption takes place. The area
surrounding the raffled border contains actin contractile protein filaments that help in
attaching the raffled border to the bone surface. Osteoclasts are located on the endosteal
bone surfaces, occasionally on periosteal surfaces and frequently at sites where active
remodeling of bone is occurring.
The process of remodeling in the adult skeleton involves a fight coupling between
bone resorption and bone formation (1, 4). Wolff’ s law states that bone remodels in order
to withstand the mechanical stresses exerted upon it (5). Under normal conditions,
remodeling causes a reduction in bone mass where there is low or no mechanical loading
on bone and formation of new bone where bone is highly loaded. Remodeling starts with a
period of activation, followed by bone resorption, reversal phase and finally to bone
formation. This is evident by the fact that almost all osteoclastic activity is followed by
osteoblastic activity. It is believed that osteoblasts mediate the signals for osteoclastic bone
resorption. Therefore, hormonal regulation of bone resorption occurs through osteoblastic
cells.
Osteoblastic MC3T3-E1 Cells
MC3T3-E1 cells are derived from newborn murine calvariae and have been reported
to exhibit a similar developmental sequence to osteoblasts and display osteoblast-like
characteristcis after repeated passages (6). It has also been shown that calcified bone tissue
is formed in MC3T3-E1 cell cultures in the same manner seen in intramembraneous
osteogenesis in vivo. They have the capacity to differentiate into osteoblasts and deposit
hydroxyapetite. Osteoblastic cells go through a developmental sequence that initiates from
proliferation of undifferentiated osteoblast precursors followed by expression of
differentiated osteoblastic phenotype (7, 8). During the initial phase, immature osteoblastic
cells actively replicate. Genes that are required for cell growth are actively expressed.
Maximal levels of type I collagen mRNA and DNA synthesis are achieved. In the
intermediate phase, cells attain confluence, display a cuboidal morphology and stop
growing. The downregulation of replication occurs in conjunction with the occurrence of
osteoblastic phenotypic markers. These include the production of alkaline phosphatase,
processing of procollagens to collagens, and secretion of extracellular matrix protein.
Alkaline phosphatase activity is minimal during active replication but increases significantly
with the onset of growth arrest. Therefore, it is thought to be coupled with the
downregulation of replication (9). The final phase of osteoblast phenotypic development is
characterized by mineralization of the extracellular matrix (7, 9). In osteoblastic MC3T3-
E1 cells, the expression of osteoblast markers follow a temporal sequence with production
of type I procollagen mRNA preceeding the induction of alkaline phosphatase, followed by
osteocalcin rnRNAs. The functional similarities that exist between MC3T3-E1 cells growth
and normal osteoblasts support the use of the MC3T3-E1 culture system as a useful model
to examine cell growth and differentiation (9).
There is a functional relationship between expression of genes in osteoblasts and
events associated with osteoblast phenotypic development. For example, high levels of
type I collagen mRNA expression during osteoblast proliferation may indicate that the
proliferative period supports the synthesis and deposition of collagen required for an
extracellular matrix competent for the ordered deposition of mineral (8). Therefore, it is
reasonable to test the effect of ascorbic acid, a requirement for collagen synthesis, on the
development of the osteoblastic phenotype. The addition of ascorbic acid to fetal rat
calvarial cells increases total collagen accumulation paralleled by higher levels of alkaline
phosphatase activity and higher levels of mineral accumulation in the cell layer. In
addition, the downregulation of proliferation is reached early with the addition of ascorbic
acid (8). Ascorbic acid increases osteocalcin synthesis and the addition of [-
glycerolphosphate accelerates the onset of mineralized nodule formation coincident with the
increase in osteocalcin expression (7). However, primary osteoblastic cultures are
complicated by the presence of various cell populations, such as fibroblasts, chondroblasts.
Investigation of osteoblastic function in a clonal cell culture model overcomes this
limitation.
The MC3T3-E1 cell line has been used to find a possible association between
collagen production and osteoblastic marker expression utilizing ascorbic acid and
inhibitors of collagen production (10). Ascorbic acid increases the expression of alkaline
phosphatase and osteocalcin in MC3T3-E1 cells. Ascorbic acid also dramatically increases
collagen matrix accumulation which forms only after exposure to ascorbic acid.
Mineralization of the extracellular matrix was greatly stimulated by ascorbic acid and [-
glycerol phosphate. However, [3-glycerolphosphate alone did not affect any of the
osteoblastic development markers. These osteoblastic markers were not expressed when
cells were grown in the absence of ascorbic acid or in presence of collagen synthesis
inhibitors. These changes in collagen matrix production are attributed to posttranscriptinal
mechanisms that ascorbic acid could modify.
Prostaglandins
Prostaglandins are powerful regulators that have both stimulatory and inhibitory
effects on bone metabolism. They have been shown to promote bone resorption (11).
Prostaglandins also mediate the bone resorptive action of other inflammatory products such
as bradykinins and interleukin-1 (12). Moreover, they play a role in the pathogenesis of
bone loss in some diseases. Examples are alveolar bone loss in periodontal disease (13)
hypercalcemia and increased bone resorption associated with malignancy (14-16) and
chronic inflammation (17). Prostaglandins and collagenase are the only resorbing factors
detected in odontogenic cysts (13). Substantial amounts of PGE2, PGF2a, and 6-keto-
PGFla are released by dental cyst capsule fibroblasts (18). Prostaglandins have also been
reported to enhance orthodontic tooth movement when given exogenously. However, this
enhancement is independent on the concentration of prostaglandins injected or the number
of injections (19). Prostaglandins may also play a role in postmenopausal osteoporosis
(20). Prostaglandins, in addition to other cytokines, increase bone resorption induced by
ovariectomy in mice. Individually, these cytokines are ineffective in causing increased
bone resorption due to estrogen withdrawal. Bone resorption occurs because of the
cumulative effects of these cytokines (21). The bone resorbing effect of prostaglandins has
been controversial since some studies have shown that prostaglandins transiently inhibit
bone resorption (22). The addition of prostaglandins, mainly PGE2, to mouse
monocyte/UMR106 cocultures greatly inhibits the formation of osteoclast like cells (23).
This effect is time and cell type dependent since this inhibition did not occur when PGE
was added after differentiation to osteoclast like cells. Furthermore, the addition of PGE2
to ST2 marrow preadipocytic cells stimulates bone resorption. However, some studies
suggest that differences in PGEz induced bone resorption/formation may be due to the
influence of coexisting osteoblasts (24). Prostaglandins cause a significant increase in the
osteoclast-like cell formation. However, this increase only occurs in the presence of
osteoblasts and is inhibited by indomethacin (24). Prostaglandins promote bone resorption
either by themselves or by acting together with resorptive agents such as cytokines. The
PGE series has been shown to be the most potent of prostaglandins in causing bone
resorption at a range of concentrations from 10-9 to 10-SM. PGF2 is less effective than
PGE and it’s ability to stimulate bone resorption is dependent on PGE2 induction. (25).
Stimulation of bone formation by prostaglandins has been demonstrated in organ
cultures where this stimulation is increased in the presence of cortisol (25). This is
mediated by cAMP and may be associated with increased insulin like growth factor-I
expression (26). Mechanical forces can elicit a response in bone cells by stretching, fluid
shear stress or impact loading (27). Prostaglandins play a role in skeletal growth in
fracture repair and impact loading (28-30). It has been suggested that impact loading
causes production of PGE2 and PGI2 which leads to increased production of growth factors
that stimulates differentiation and replication of osteoblasts. Therefore, impact loading can
lead to a prolonged period of increased bone formation (31). Zaman and co-workers found
an increase in the production of PGE, PGI2 and glucose 6-phosphate dehydrogenase
activity that was blocked by indomethacin. There is also an increase in PGE2 release in
bone cells that are subjected to strain (32). It has been shown that fluid shear stress
increases the intracellular cAMP, PGE and IP (33, 34). Stimulation of bone formation
and resorption by prostaglandins involves replication and differentiation of osteoclast and
osteoblast precursors and may be partly mediated by cAMP (35).
Prostaglandins are produced by osteoblasts and adjacent cells to the bone marrow.
Some stimulators of bone resorption can increase prostaglandin production while inhibitors
of bone resorption can prevent it. Many bone resorbing factors mediate their effects
through production of prostaglandins. Resorption stimulators include the cytokines IL-1
and TNF, growth factors such as TGF-c and TGF-, as well as hormones including PTH,
PTH related peptide (PTHrP), 1,25 (OH)2D3, and thyroid hormone. Glucocorticoids, IL-4
and nonsteroidal antiinflammatories inhibit bone resorption and prostaglandin production
(36, 37). It has also been reported that prostaglandins can induce their own production by
stimulating prostaglandin G/H synthase-2 (PGHS-2). This has been shown in vitro in
MC3T3-E1 cells (38, 39).
The first step in prostaglandin synthesis is the release of arachidonic acid from
membrane phospholipids by phospholipase A or by phospholipase C and diacylglycerol
lipase (Fig. 1). Prostaglandins are made by the conversion of arachidonic acid to
prostanoids via prostaglandin G/H synthase (PGHS). This conversion involves a
cyclooxygenase reaction that converts arachidonic acid to PGG2 and a peroxidase reaction
that converts PGG2 to PGH2. Intracellular isomerases and reductases convert PGH2 to
PGE, PGD, PGI2, PGF2a, and thromboxane A2 (35, 40). Regulation of prostaglandin
production is achieved in two ways. First by differential mobilization of arachidonic acid
from membrane phospholipids and second by alteration in PGHS function (40). There are
two isozymes for PGHS that are encoded by different genes. PGHS-1 is constitutively
expressed and is little regulated, while PGHS-2 is inducible by multiple factors. PGHS-2
acts in acute responses such as inflammation, whereas PGHS-1 has a housekeeping
function by continuously producing prostanoids. The stimulators of prostaglandin
production are IL-1, TNF, bradykinin, TGF c and 13, as well as parathyroid hormone
(PTH), parathyroid hormone-related peptide (PTH-rP), 1,25 (OH)2 D3, and thyroid
hormone (12, 37, 41, 42). These hormones and cytokines exert their action by increasing
the expression of PGHS-2 and by stimulating the release of arachidonic acid. Interleukin-4
and glucocorticoids are inhibitors of prostaglandin production. They act by inhibiting
PGHS-2 or by decreasing arachidonic acid release (41). Finally, sex hormones decrease
PTH and IL-1 stimulated prostaglandin production (20, 43). Prostaglandins can also
amplify their own production by inducing PGHS-2 (38, 41). This effect is greater with
PGF2a and PGD2 than with PGE2. Unlike most signalling molecules, prostaglandins are
not stored but are continuously released to the cell exterior as soon as they are produced.
They affect the cells that produce them and the cells in their immediate surroundings.
Therefore prostaglandins are considered autocrine and paracrine stimulators.
Prostaglandins are secreted from their producing cells and bind cell surface
receptors. There are different prostaglandin receptors on different tissues such as liver,
smooth muscle, fat cells, corpus luteum, leukocytes, platelets, and brain. The biological
activities mediated by prostaglandins binding to these receptors include contraction and
relaxation of smooth muscle, inhibition of gastric acid secretion, inhibition of inflammatory
mediator release, immunoregulation, inhibition of autonomic neurotransmitter release,
inhibition of platelet aggregation, luteolysis, and myometrial contraction. There is a
specific receptor for each of the prostaglandins: PGD2, PGE2, PGF2a, PGI2, and TXA2
bind to the DP, EP, FP, IP, and TP receptors, respectively. There are at least four EP
receptor subtypes (EP1, EP2, EP3 and EP4) and four EP3 receptor subtypes (EP3A,
EP3B, EPC, and EPD). All these receptors have similar structural characteristics including
seven transmembrane domains, but different ligand specificties and signal transduction
pathways (44). Each of these receptors elicits responses by coupling with G proteins and
activating secondary messenger systems. Intracellular second messengers are Ca2+ and
cAMP depending on the G protein coupled to the PG receptor. All prostaglandin receptors
are considered to be functional receptors since they have a role in autoregulation and their
binding site is open to modulation by ligands (44). EP2 and EP4 receptors stimulate cAMP
production and function through the activation of adenylate cyclase to mediate an anabolic
effect (45).
cAMP Mediated Signal Transduction
Signal transduction starts by binding of a ligand (i.e. hormone or cytokine) to it’s
receptor (Fig. 2). Ligand binding causes conformational changes in it’s receptor and
activates GTP-proteins (Gi, G or Gq) that transmit a signal to adenylate cyclase or
phopholipase C. Multiple signal transduction mechanisms have been described for
prostaglandins in osteoblastic cells. This leads to the production of second messangers.
These include calcium entry, IP3 and DAG release by PLC, DAG release by PLD, as well
as cAMP responses in the osteoblastic cells. The two major signal transduction pathways,
protein kinases A (PKA) and C (PKC), are activated primarily by cAMP and diacylglycerol
(DAG), respectively. PGE is known to activate PKA and PKC in osteoblast-like cells
(46). PGE2 increases cAMP production via phosphoinosidtide (PI) hydrolysis in
osteoblastic-like cells (47), an example of cross-talk (48). PGF is also known to activate
PKC, PKA as well as the mitogen-activated protein (MAP) kinase pathway through
different G proteins (49). PGF2a also induces Ca+ influx from extracellular space via a
different pathway that PI hydrolysis is stimulated (50).
In the cAMP/PKA pathway, the binding of a specific ligand will cause the
activation of a G protein, which in turn will activate or inhibit adenylate cyclase. Upon
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activation, adenylate cyclase produces cAMP, which binds cooperatively to two regulatory
sites of PKA, releasing the active catalytic subunit (48). This catalytic subunit translocates
to the nucleus where it phosphorylates a number of cytoplasmic and nuclear proteins on a
serine residue, for example, position 133 of CREB (51) and position 117 of CREM (52).
The phosphorylation of transcriptional factors mediates transcriptional regulation of various
genes. The binding of phosphorylated CREB/ATF factors at cAMP-response element
(CRE) sites causes transcriptional activation or repression of target genes. The expression
of these factors is not induced. They are mainly regulated by differential phosphorylation
CREM
Prostaglandins act by inducing or repressing gene expression in osteoblastic cells.
CREM, the cAMP response element modulator, is a member of CREB/ATF family. The
transcription of CREM results in multiple proteins by alternative splicing and promoter
utilization. These proteins have different DNA binding affinities that act as transcriptional
activators and repressors by binding to CREs in the promoter region of genes. CRE is an
eight base pair palindromic sequence (TGACGTCA). Many DNA binding proteins, for
example CREB, jun, fos, and C/EBP, have certain features that facilitate binding to DNA
(53, 54). All CREB/ATF transcription factors contain the basic domain/leucine zipper
motifs and bind as dimers to cAMP-response elements (CRE). Leucine zipper is a coiled
sturcture responsible for dimerization and the basic region is involved in recognition and
binding to DNA. Dimerization is required for binding to DNA and there is a dimerization
code indicating that the zipper regions of all proteins will not dimerize with each other (53).
CREM, like other trascriptional factors, exhibits a structural diversity in that it can form
homodimers as well as heterodimers. The function of CRE-binding proteins is modulated
by phosphorylation by several kinases. CREM is the only member of the CREB/ATF
family that is inducible by cAMP. This induction is rapid and does not require protein
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synthesis. Upon activation by cAMP mediated binding of transcription factors, there is a
rapid increase in the CREM transcription, which peaks after two hours and declines to
basal levels by five hours. This feature classifies CREM as an early response gene (55).
As mentioned above, CREM gene has multiple exons that gives rise to activators as
well as antagonists of cAMP-inducible transcription. This property is unique to CREM
within the CREB/ATF family of transcription factors. This diversity is due to differential
splicing (56). The CREM gene encodes two glutamine rich domains (Q1 and Q2) that are
responsible for transcriptional activation, a kinase inducible domain or phosphorylation box
(P-box) that includes several phosphorylation sites for various kinases, and two DNA
binding domains (DBDI and II) (57, 58). The DNA binding domains constitute a leucine
zipper and a basic region (55, 59). Upon phosphorylation, the activator protein undergoes
a conformational change that exposes the glutamine rich domains, allowing them to interact
with the transcription machinery (60). The CREM antagonists c, [ and 3’ lack Q1 and Q2
domains and block cAMP-induced transcription (58). CREMx is another isoform that
includes the glutamine rich domains and acts as a transcriptional activator (56). Upon
activation of adenyl cyclase pathway, a serine residue at position 133 of CREB and at
position 117 of CREMx is phophorylated by PKA. The function of glutamine rich
domains is activation of transcription. Each glutamine rich domain can function as an
activator by itself, as in CREM isoforms x l and x2. The activation of glutamine rich
domains are additive on the magnitude of transcriptional activation when both present, with
Q2 being more powerful than Q1 (58). Repression occurs either by the binding of
nonactivating homodimers or by heterodimerizing with CRE binding activators, thus
blocking their activation. Nonactivating homodimers such as CREM or, 15 and 7 compete
with transcription activators for binding to CREs and down regulate cAMP-stimulated gene
expression.
13
ICER
The CREM gene also encodes a group of small repressors. The CREM gene
includes two promoters, P1 and P2 (59). P2 is an intronic promoter that that directs the
transcription of ICER (inducible cAMP early repressor). This intronic promoter is located
between the second glutamine rich domain and the 7 exon (59). ICER is the only inducible
product of CREM because it is initiated at the intronic promoter P2 that contains four CREs
in tandem. Therefore, ICER is strongly inducible by cAMP (61). This feature of ICER
gene renders it’s expression to be rapid and transient. ICER expression does not reuire de
novo protein synthesis (55, 62). The expression pattern of ICER shows that CREM
belongs to the class of the immediate early response genes. ICER is a small protein of 120
amino acids with a predicted molecular weight of about 13 KDa. Due to alternative
splicing, ICER transcripts yield four isoforms: I, I,, II, and II. All ICER isoforms lack
the Q and kinase inducible domains of CREM but include either DBDI or DBD II which
contain the leucine-zipper and basic region. ICER I and II isoforms include the CREM /
domain while the ICER I, and II3, do not (59). Therefore, ICER can bind to DNA but will
not activate transcription. Also, ICER can heterodimerize with CREMx and other CREM
proteins. This would indicate that ICER prevents transcription by occupying the CRE sites
as inactive homodimers or by dimerizing with activators and blocking them by the
formation of non-functional heterodimers. Hence it is a more potent repressor than
CREMc or CREMe. ICER induction is thought to play a role in the transient nature of
cAMP-induced gene expression. The kinetics of ICER induction are characteristic of an
immediate early gene. Following cAMP stimulus, there is a rapid rise in CREM transcript
that peaks at 2-4 hours followed by a rapid down regulation which is delayed by
cycloheximide, an inhibitor of protein synthesis (55). The prolonged inducibility by
cycloheximide of cAMP-stimulated gene expression suggests that a de novo synthesized
protein, such as ICER, may be responsible for attenuating transcription. The presence of
an inducible repressor in a particular cell type or physiological situation could indicate that
there is a mechanism for attenuation of gene expression after activation by cAMP (63).
CREM proteins play an important role in the physiology of the pituitary gland,
spermatogenesis, circadian rhythms, and in the molecular basis of memory. Circadian
rhythms, 24 hour oscillations in an organism’s physiology, in mammals can be seen in the
pineal gland, where the expression of CREM gradually increases at night reaching a peak at
around 2 am, and decreases to basal low level 3 hours after dark-light transition. (59). A
hypothalamic circadian clock is located in the suprachiasmatic nucleus (SCN). The
adrenergic stimuli originated from suprachiasmatic nucleus are responsible for the elevated
expression of CREM in the pinealocytes at night (64). Moreover, CREM transcripts are
abundant in testes. Prepubertal testes mainly express repressor forms of CREM while
adult testes express the activator form (56). This developmental switch is regulated
through a neuroendocrine axis by follicle stimulating hormone (65). The neuroendocrine
axis of CREM expression has been shown in hypophysectomized mice (65). The removal
of the pituitary gland diminishes the expression of CREMx in the testis. The tissue specific
expression of CREM is indicative of it’s important role in regulation of the cAMP
responses (57). The fact that ICER is an inducible repressor and may play a role in the
autoregulation of CREM shows the rhythmicity of this gene which is a hallmark of a
circadian gene expression. ICER expression has been shown in tissues of neuroendocrine
origin such as pineal, pituitary, and adrenal glands (59), as well as non-neuroendocrine
tissues such as rat brain (66) and T-lymphocytes (67). ICER accounts for rapid decrease in
tyrosine hydroxylase enzyme that catalzes the first and rate-limiting step in catecholamine
biosynthesis. This enzyme is located in the central nervous system, sympathetic nervous
system and the neuroendocrine cells of the adrenal medulla of the adult mammals (68).
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Figure 1 Diagrammatic representation of PG biosynthesis. This figure was
adapted from Smith (40).
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Figure 2 PGE2 signal transduction pathway through the cAMP-PKA
pathway.

HYPOTHESES
PTH induces ICER in osteoblastic MC3T3-E1 cells and cultured neonatal mouse
calvariae through the cAMP/PKA pathway (62). Prostaglandins have similar functions to
PTH. PGE:, the most potent bone resorbing prostaglandin is also linked to the PKA
signaling pathway in mouse bone cell cultures (24). Also, it has been observed that
MC3T3-E1 cells respond differently to a signal depending on their state of differentiation.
Therefore, we hypothesize that
Prostaglandins, which signal through the cAMP-PKA pathway, will transiently induce
ICER in MC3T3-E1 cells and neonatal mouse calvariae
Induction of ICER by prostaglandins will vary with the differentiation state of the cells.
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SPECIFIC AIMS
To determine if prostaglandins can induce ICER mRNA expression in MC3T3-E1
cells and neonatal mouse calvariae.
Confluent MC3T3-E1 cells and calvariae from seven day old mice will be treated
with 10 nM PTH or various concentrations of PGE2, or PGFza for 2 hours. Total
RNA will be extracted from one plate of cells or three hemicalvariae for treatment
group and quantified at 260 and 280 nm. 3 tg of RNA will be used for reverse
transcription (RT). The RT product will be amplified by polymerase chain reaction
(PCR) using primers for ICER, GAPDH, and osteocalcin. ICER induction will also
measured by Northern blot analysis. RNA will be electrophoresed on an agarose
gel, then transferred and immobilized onto a nylon membrane. The immobilized
RNA will be probed for ICER, osteocalcin, and actin mRNAs.
To determine the time course of ICER induction by prostaglandins in MC3T3-E1
cells.
Confluent MC3T3-E1 cells will be treated with 1 oM M PGEz for 1, 2, 4, 6, and 10
hours. Total RNA will be extracted and quantitated at 260 and 280 nm. ICER,
osteocalcin, actin and glyceraldehyde phosphate dehydrogenase (GAPDH) will be
measured by reverse transcriptase PCR (RT-PCR) and/or Northern analysis.
To determine if the induction of ICER is dependent on the differentiation state of
MC3T3-E1 cells.
20
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Confluent MC3T3-E1 cells will be grown with or without ascorbic acid for 1 to 3
weeks and treated with PTH, PGE2, and PGF2a for two hours. Total RNA will be
extracted and quantitated at 260 and 280 nm. ICER, osteocalcin and
glyceraldehyde phosphate dehydrogenase (GAPDH) will be measured by reverse
transcriptase PCR (RT-PCR).
MATERIALS AND METHODS
Materials
PGE2 and PGF2 were purchased from Sigma Chemical Company, St. Louis, MO
and prepared as a 0.01 M stock solution in ethanol. They were diluted in culture medium to
the appropriate concentration. Bovine PTH (1-34) was purchased from Sigma Chemical
Company (St. Louis, MO). A 0.1 mM PTH stock solution was prepared in a vehicle
containing 1 mg/ml bovine serum albumin (BSA) and 0.001 N HC1. PTH was then diluted
in medium at least 1000 fold. L-Ascorbic acid phosphate magnesium salt n-hydrate
(phosphoascorbate) was purchased from Wako Pure Chemical Industries, LTD and used in
cultures at 50 ].tg/ml. ICER cDNA was generated by cloning a 169 bp PCR product into
the TA vector. Rat osteocalcin (BGP) cDNA was the kind gift of Dr. Vicki Rosen,
Genetics, Institute, Cambridge, MA. Chick [-actin cDNA was kindly provided by Dr.
Donald Cleveland (Johns Hopkins University, Baltimore, MD).
Cell Culture
MC3T3-E1 cells were plated at 5000 cells/cm2 in 100 mm culture dishes (Costar,
Cambridge, MA), and maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco
BRL, Grand Island, NY) containing 10% heat inactivated fetal calf serum (FCS; Gibco,
Grand Island, NY), penicillin (100U/ml), and streptomycin (50 mg/ml). The cells were
grown in a humidified incubator in an atomosphere of 5% CO, and 95% air at 37C. The
medium was changed every three to four days and the cells were grown to confluence. The
cells were treated on the sixth day.
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Calvariae
Timed-pregnant female CD-1 mice were obtained from the Charles River
Laboratory, Boston, MA. Hemicalvariae of 6-8 day-old offspring were aseptically
dissected and precultured for 24 hours in 35 mm plastic culture dishes (Costar, Cambridge,
MA) containing 2 ml BGJ medium (Gibco BRL, Grand Island, NY) supplemented with 1
mg/ml BSA, 100 pg/ml ascorbic acid and 1 mM proline for 24 hours prior to hormone
treatment.
RNA Extraction
RNA extraction was performed using the method of Chomczynski and Sacchi (69).
Pools of six calvariae were homogenized using a polytron (Kinematica, Kriens, LU,
Switzerland) in 4M guanidinium isothiocyanate (GTC). Cells were lysed in GTC without
homogenization. Following lysis, 0.2ml of sodium acetate, pH 4, 2 ml of water-saturated
phenol (Gibco, Grand Island, NY), and 0.5 ml of chloroform-isoamyl alcohol (24:1) were
added. Samples were left at 4C for 15 minutes and centrifuged at 9000 rpm for 20
minutes at 4C. The aqueous phase was removed, added to one volume of isopropanol and
precipitated at-80C for 15 minutes. The samples were centrifuged again at 9000 rpm for
20 min at 4C. The pellets were resuspended in 0.3 ml guanidinium isothiocyante. The
RNA was precipitated with 1 volume of isopropanol and washed with 80% ethanol.
Precipitated RNA was lyophilized and dissolved in 50 tl of water. The RNA was heated at
65C for 10 minutes. RNA content was quantitated by absorbance at 260 and 280 nm
using a Pharmacia Genequant RNA/DNA calculator. The OD26o to OD80 ratio was used to
assess purity of the RNA preparation.
RT-PCR
All materials were obtained from Gibco BRL (Grand Island, NY). 3 tg of RNA
was incubated in a 50 1 reaction volume containing oligo dT (1.75 mM final
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concentration), 5x buffer, 500 mM dNTPs, 2 mM dithiothreitol, 1U/ml RNase inhibitor
(Stratagene, La Jolla, CA), and 13.5 U/ml M-MLV RT enzyme. 5 gl of RT product was
incubated with 1.5 mM magnesium chloride, 5 nM primers, 25 U/ml of Taq polymerase,
10X PCR buffer, and water to a final volume of 50 tl. The amplification cycle for ICER
consisted of 3 minute denaturation at 94C for the first cycle and 45 seconds for the
remaining cycles, annealing at 65C for 45 seconds, and extension at 72C for 2 minutes
and 5 minutes at the end. Primers (Gibco BRL) were designed according to the ICER
sequence reported by Molina et al. 1993 (55). The 5’ primer corresponded to the 5’
untranslated region of ICER (5’-TATGCAAAAGCCCAACATGG-3’; primer A, Figure 3)
upstream of q and DNA binding domains. The 3’ primer spans nucleotides 1068-1090
downstream ofDBD II (5’-CTACTAATCTGTTTTGGGAGAGC-3’; primer C, Figure 3).
Murine glyceraldehyde phosphate dehydrogenase (GAPDH) was amplified using specific
primers (Clontech Laboratories, Inc., Palo Alto, CA) and served as an internal control.
Osteocalcin primers (Gibco BRL, Grand Island, NY) were used to amplify osteocalcin.
The same conditions were used for the amplification of GAPDH and osteocalcin with the
exception of the annealing temperature which was 60C for GAPDH and 67C for
osteocalcin. The number of cycles were 25 for ICER and 22 for GAPDH and osteocalcin.
Northern Blot Analysis
A gel containing 1% agarose and 3% formaldehyde was used for Northern blot
analysis. 20 gg of RNA from MC3T3-E1 cells or 12.5 tg of RNA from calvariae were
lyophilized. Prior to loading on the gel, 0.5 tg of ethidium bromide were added to each
sample. The gel ran for three hours on ice and RNA was transferred to a nylon membrane
(Genescreen; New England Nuclear Corp., Boston, MA) using positive pressure
(Posiblotter, Stratagene, La Jolla, CA). To immobilize the RNA, a UV Stratalinker
(Stratagene, La Jolla, CA) was used. The membranes were prehybridized at 42C for three
hours in rotating cylinders (Techne Hybridizer, Princeton, NJ). In addition to the
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prehybridization buffer (5prime to 3prime, Boulder, CO), 50% formamide, ss DNA and
yeast tRNA (5 prime to 3 prime, inc. Boulder, CO), were added to the prehybridization
buffer. Filters were hybridized overnight in hybridization buffer containing 50%
formamide, 20% dextran (5prime to 3prime, Boulder, CO), 0.04 mg/ml ssDNA and
ytRNA, [3p]dCTP or [32p]dGTP-labled cDNA probes (3000 Ci/mml, New England
Nuclear Research Products, DuPont Co, Wilmington, DE) for actin and osteocalcin. The
activity of denatured cDNA probes were 2-5 x 106 cpm/ml. Both radionucleotides were
used to label the ICER probe. Filters were washed once in 1% sodium dodecyl sulfate
(SDS)/1X SSC at room temperature for 10 minutes and then heated to 65C in 0.1%
SDS/0.1 X SSC, followed by several washes in 0.1% SDS/0.1 X SSC at room
temperature. Filters were exposed to Kodak film with an intensifying screen at-80C for
1-3 days. Filters were stripped with boiling 0.1% SDS/0. lxSSC between hybridizations.
RESULTS
Our first goal was to determine if prostaglandins could induce ICER mRNA in
MC3T3-E1 cells and neonatal mouse calvadae. Confluent MC3T3-E1 cells were treated
with PTH at 10 nM and PGE2 and PGFz at 1 ktM for 2 h. ICER mRNA levels were
determined by RT-PCR using primers A and C (Fig. 3). PGE and PGF induced ICER
mRNA. (Fig. 4) The induction of ICER by these prostanoids was not as strong as by PTH
at 10 nM. PGF was less effective than PGE2 or PTH. PTH and PGE induced all ICER
isoforms as determined by RT-PCR using primers A and C. In all cases four bands
consistent with the predicted sizes of 779, 743, 382, and 346 base pairs were seen. These
corresponded to the ICER isoforms I, Iq(, II and IIq((62). Expression of GAPDH was
similar in all samples.
To determine the dose response relation for prostaglandin induction of ICER,
MC3T3-E1 cells were treated with various concentrations of PGEz and PGFz, for 2 h and
ICER mRNA levels were detemfined by RT-PCR. The maximal induction of ICER was at
10 t-tM PGE2. ICER mRNA levels returned to basal levels at 0.1 nM PGE/ (Fig. 5).
Induction by PGF at 1 ktM was lower than at 100 nM in MC3T3-E1 cells. (Fig. 6).
PGF2 had a maximal effect at 100 nM and returned to basal levels at 0.1 nM. Expression
of GAPDH and osteocalcin was similar in all samples.
To determine whether prostaglandins and PTH induced ICER expression in bone
tissue, neonatal mouse calvariae were treated with PGE2 and PGF2, at 1 M and PTH at 10
nM for 2 h. ICER mRNA levels were determined by Northern blot analysis and RT-PCR
using primers A and C. All three agonists induced ICER mRNA in neonatal mouse
calvariae at 2 h. PGF was less effective than PGE2 or PTH. (Fig. 7a, 7b) A dose
response relation was also determined for PGE2 induction of ICER in neonatal mouse
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calvariae at 2 h. PGE2 induction of ICER was dose dependent. The response was
maximal at 1 pM and decreased to low levels at 1 nM. (Fig. 8). Expression of GAPDH
and osteocalcin were similar in all samples.
To determine the time course of ICER induction by prostaglandins, MC3T3-E1
cells were treated with 1 pM PGE for 1, 2, 4, 6 and 10 h (Fig. 9). RNA was subjected to
RT-PCR using primers A and C. The induction of ICER reached a maximum level at 2 h
and returned to baseline by 6 h. ICER induction by PGE in MC3T3-E1 cells was also
detectable by Northern analysis, but only at 1 pM. Expression of GAPDH mRNA was
equivalent in all samples.
To determine if the induction of ICER by prostaglandins was dependent on the
differentiation state of MC3T3-E1 cells, cells were cultured in the presence or absence of
50 tg/ml phosphoascorbate for up to three weeks. After 1, 2 and 3 weeks of culture cells
were treated with PTH and prostanoids for 2 h and analyzed for ICER mRNA levels by
RT-PCR. At week 1, there was no induction of ICER by PTH or prostanoids in the
presence or absence of phosphoascorbate (Fig. 10). At week 2, PTH and prostanoids
induced ICER in cells grown with and without ascorbate. However, there was a marked
increase in ICER induction by PTH in cells cultured in the presence of phosphoascorbate
(Fig. 1 l a and 1 lb). Prostaglandins showed a slight enhancement of ICER induction in the
presence of phosphoascorbate. At week 3, all agonists showed a higher induction of ICER
in the presence or absence of phosphoascorbate (Fig 12a and 12b). The highest ICER
levels were induced by PTH, followed by PGE2 and then PGFa regardless of the age of
the culture or treatment medium. Northern blot analysis of RNA at week 1 showed no
detectable osteocalcin production in any of the treatment groups. At weeks 2 and 3, all
cells expressed osteocalcin; there was greater osteocalcin mRNA in the phosphoascorbic
treated cells. Analysis of the week 2 and 3 Northern blots by densitometry demonstrated
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that all ascorbate treated samples had enhanced osteocalcin expression. It is also evident
that prostanoids decreased the expression of osteocalcin compared to PTH and control.
ICER was too weak to be detected by Northern blot analysis at any of the time points (data
not shown). Expression of GAPDH and osteocalcin was similar in all samples.
DISCUSSION
PGE induced all of the known ICER isoforms in osteoblastic MC3T3-E1 cells.
This response was rapid and transient. PGE2 induction of ICER in MC3T3-E1 cells had a
peaked at two hours and then declined to baseline levels by ten hours as determined by RT-
PCR. PGE2 induces it’s biological effects mainly through EP receptors. EP2 and EP4
receptors are coupled to adenylate cyclase through G (44). This enables PGE2 to stimulate
cAMP production and activate PKA. Since ICER induction is tightly coupled to the cAMP-
PKA pathway in osteoblastic cells, it is reasonable to hypothesize that PGE2 induces ICER
via EP2 and/or EP4 receptor binding.
PGF2, induction of ICER was lower than either PTH or PGE2. The induction of
ICER by PGF_, peaked at 100 nM and was lower at 1 tM. The actions of PGF2 are
carried out primarily through FP receptors. FP receptors interact with a Gq protein and
activate phospholipase C (44). Phospholipase C in turn hydrolyzes phophoinositide (PI)
into diacylglycerol (DAG)and inositol triphosphate (IP3). This ultimately leads to an IP3
mediated Ca+ release from intracellular pools and activation of PKC by DAG. It has been
shown that PGF induces Ca/ influx in a dose dependent manner (50). This study
reported that Ca/ influx is significantly stimulated by PGF even in the presence of a Ca/
antagonist that was maximal at 10 nM. A concentration of PGF2 above 10 nM caused a
less than maximal stimulation. Since PGFz stimulation of IP3 follows a normal curve, it
seems that PI hydrolysis and Ca2+ influx are carried out by different pathways. This also
may explain the lower induction of ICER by PGF2 at higher concentrations. The induction
of ICER may be carried out by a different pathway that is concentration sensitive. For
example, it is known that PGF2 is partially capable of inducing a response through PKA.
The lower level of induction of ICER can also be explained by this partial use of PKA by
PGF. It can also be possible that PKC and PKA pathways converge at the level
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of transcriptional activity in MC3T3-E1 cells (38). It would be plausible that activation of
PKC could also induce CREM but at a lower level. The level of ICER induction in
MC3T3-E 1 cells could not be consistently detected by Northern Blot analysis. This may be
attributed to several factors such as sensitivity of different batches of MC3T3-E1 cells to
prostaglandins or the state of differentiation of these cells.
PTH, PGE2 as well as PGF also induced ICER mRNA in neonatal mouse
calvariae. ICER induction by PTH was strongest and PGF had the weakest response.
The mRNA extracted from mouse calvariae was subjected to Northem blot analysis as well
as RT-PCR. A classical dose response relationship was not evident on the Northern
analysis. However, RT-PCR indicated a dose response pattem with a peak at the highest
concentration (1 tM) and decreased induction of ICER corresponding to the decrease in the
dose of PGE2.
MC3T3-E1 cells were treated with ascorbic acid to induce differentiation.
Osteocalcin mRNA was measured as a marker of mature osteoblasts. The effect of
ascorbic acid on the differentiation of MC3T3-E1 cells was not evident at the first week of
incubation, as osteocalcin was not expressed. However, cells expressed osteocalcin after
two and three weeks of culture as shown by the Northern blot analysis. Cells cultured with
ascorbic acid expressed more osteocalcin than cells cultured without ascorbic acid.
However, differentiation was not totally dependent on ascorbic acid since cells without
ascorbic acid also expressed osteocalcin at weeks 2 and 3. These data indicate that high cell
density may also increase differentiation. In studies that measured osteoblast differentiation
as measured by alkaline phophatase activity, no change was detected in the onset of alkaline
phosphatase activity in presence of ascorbic acid (9). However, ascorbic acid enhanced
alkaline phosphatase activity in mature osteoblasts compared to controls. The same study
found the regulation of collagen biosynthesis to be independent of ascorbic acid. These
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studies indicate that the presence of ascorbic acid is not required for the development and
onset of osteoblastic marker expression and that it can affect only some of these markers.
Expression of ICER in ascorbic acid treated cells did not show an increased
response compared to controls at first week. ICER mRNA increased in both ascorbic acid
treated and control cells in the following weeks. However, the differentiation state of
MC3T3-E1 cells did not increase the induction of ICER by different agonists remarkably.
This would probably indicate that the induction of ICER by these agonists is not totally
dependent on the differentiation state of these cells.
Possible roles of ICER in PG response:
It has been shown in many studies that exogenous prostaglandins (PGE, PGFa,
PGD2, and PGI2)can induce PGHS-2 mRNA in osteoblastic MC3T3-E1 and Pyla cells
which leads to increases in protein and medium PGE2 (38, 41). Furthermore, this
induction occurs through the cAMP/PKA pathway through enhancement of transcription in
MC3T3-E1 cells. In MC3T3-E 1 cells the decline of PTH stimulated PGHS-2 transcription
required de novo protein synthesis (62). It can be hypothesized that the attenuation of the
induced PGHS-2 gene transcription may be mediated by a protein such as ICER. This is
speculated since the peak of ICER protein corresponds to the decline in PGHS-2 mRNA.
Further, it can be hypothesized that the attenuation of transcription of other primary
resoponse genes that occur through the PKA pathway may be mediated by ICER.
Exogenous PGE induces the expression of early response genes such as c-fos, c-
jun, jun-B and egr-1 in calvariae and tibiae of 5 week old rats (70). jun and fos are
members of a family of protooncogenes whose products form a dimeric protein complex
called activator protein-1 (AP-1). AP-1 is a transcriptional factor that mediates the
activation of many genes. Weinerb reported that the induction of these early-response
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genes is rapid and transient since the mRNA levels return to baseline (70). Moreover, c-
fos promoter contains several regulatory sequences including CREs that can mediate a
cAMP activation of this gene via a PGE2 signal. Since PGE2 causes the induction of ICER
in osteoblastic cells, it is plausible to assume that the transient response of jun and fos
may be due to transcriptional attenuation by ICER.
It has been shown that prostaglandins influence the differentiation of osteoclast
precursors (22, 23). This influence is dependent on the type and dose of the administered
prostaglandin as well as the type of cell used. The differentiation of osteoclasts requires the
interaction between hematopoietic osteoclast precursor cells and stromal or osteoblastic
cells (43). When prostaglandin E is added to murine bone marrow macrophages prior to
the addition of stromal cells, osteoclastic differentiation is enhanced (71). This effect was
reproduced by 8-bromo-cAMP. Paradoxically, Quinn and colleagues showed that several
types of prostaglandins inhibit the osteoclast differentiation of precursor cells (mouse
monocyte/UMR106 cocultures)(23). This effect was time dependent since the addition of
prostaglandin after the differentiation of these cells greatly reduced this inhibition. PGE
was found to be more potent than PGE and PGF2a. However, in the same study
prostaglandins increased the amount of lacunar bone resorption in another cell line, ST2
preadipocytic cells. They concluded that the effects of prostaglandins on osteoclast
differentiation in vitro are highly dependent on the type of bone derived stromal cells
supporting this process (23). The addition of PGE2 increased intracellular cAMP levels in
both cell types. Moreover, this cAMP increase is mimicked by the addition of PTH or
forskolin. This further raises the possibility of a PKA signal transduction and gene
expression which would imply a possible role of ICER in the attenuation of the response.
Fuller and Chambers showed that prostaglandins transiently inhibit bone resorption when
added to isolated osteoclasts in vitro (22). This calcitonin like inhibitory effect is thought to
be due to activation of cAMP formation in osteoclasts. Since prostaglandins may
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"transiently" inhibit osteoclast function through cAMP, it is plausible to question the cause
of this transitory response and whether ICER plays a role in this response.
Prostaglandins have a stimulatory effect on bone formation. This is thought to
occur in part through an increase in the production of insulin-like growth factor-I (IGF-I)
(26). This hypothesis is supported by the fact that IGF binding protein-3 decreases
collagen synthesis in mouse calvarial organ cultures stimulated by cortisol and PGE2.
Forskolin has a similar anabolic effect whereas phorbol ester does not elicit this response
suggesting that the cAMP-PKA pathway mediates the increase in IGF-I production.
Therefore, it will be interesting to determine the possible role of ICER in regulating PGE2
stimulated IGF-I production and bone formation in response to PGE2.
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Figure 3 Schematic representation of ICER transcripts and primers used for
PCR.
Primers A and C (arrows) were used to identify ICER transcripts in MC3T3-E1
cells and mouse calvariae. Primer A correstponds to the unique untranslated region of
ICER. Primer C is located downstream of DBDII. Predicted sizes of the PCR products are
indicated on the right.
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Figure 4 PGE2 and PGF2a induce ICER mRNA in MC3T3-E1 osteoblastic
cells.
Cells were treated with 1 tM PGEz, 1 tM PGFz or 1 nM PTH for 2 h. RNA was
extracted and subjected to RT-PCR as described in Materials and Methods.
37
872
603
ICER
310
1078
872 GAPDH
lgure 4
38
Figure 5 PGE produces a dose-dependent induction of ICER mRNA in
MC3T3-E 1 osteoblastic cells.
Cells were treated with vehicle, PTH (10 nM) or PGEz (0.1 nM to 10 gM) for 2 h.
RNA was extracted and subjected to RT-PCR as described in Materials and Methods.
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Figure 6 PGF:a produces a dose-dependent induction of ICER mRNA in
MC3T3-E1 osteoblastic cells.
Cells were treated with vehicle, PTH (10 nM ) or PGF (0.1 nM to 10 tM) for 2
h. RNA was extracted and subjected to RT-PCR as described in Materials and Methods.
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Figure 7a PGE2 and PGF2a induce ICER mRNA in neonatal mouse calvariae.
Calvariae were treated with vehicle, 1 tM PGE2, 1 M PGF, or 1 nM PTH for 2
h. RNA was extracted and subjected to RT-PCR as described in Materials and Methods.
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Figure 7b PGE2 and PGF2c induce ICER mRNA in neonatal mouse calvariae.
Calvariae were treated with vehicle, 10 nM PTH, 1 gM PGE or lgM PGFc, for 2
h. RNA was extractred and subjected to Northern blot analysis as described in Materials
and Methods.
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Figure 8 PGE2 causes a dose-dependent induction of ICER mRNA in
neonatal mouse calvariae.
Calvariae were treated with vehicle, 10 nM PTH, 1 nM to 1 gM PGE for 2 h.
RNA was extracted and subjected to RT-PCR as described in Materials and Methods.
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Figure 9 PGE2 produces a time-dependent induction of ICER mRNA in
MC3T3-E 1 osteoblastic cells.
MC3T3-E1 cells were treated with vehicle or 1 tM PGE2 for 1 to 10 h. RNA was
extracted and subjected to RT-PCR as described in Materials and Methods.
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Figure 10 MC3T3-E1 cells cultured for one week express very low ICER and
osteocalcin regardless of whether they are grown in the presence or absence of ascorbic
acid.
MC3T3-E1 cells were grown in the presence or absence of 50 gg/ml
phosphoascorbate for 1 week. Cells were treated with 10 nM PTH, 1 gM PGE or 1 laM
PGF2c for 2 h. RNA was extracted and subjected to RT-PCR as described in Materials and
Methods.
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Figure lla PTH, PGE: and PGF_ induce ICER in MC3T3-E1 cells cultured
for two weeks in the presence or absence of ascorbic acid.
MC3T3-E1 cells were grown in the presence or absence of 50 pg/ml
phosphoascorbate for 2 weeks. Cells were treated with 10 nM PTH, 1 tM PGE or 1 gM
PGF for 2 h. RNA was extracted and subjected to RT-PCR as described in Materials and
Methods.
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Figure llb Osteocalcin expression is higher in ascorbate-treated compared to
ascorbate untreated MC3T3-E1 cells cultured for two weeks.
MC3T3-E1 cells were grown in the presence or absence of 50 tg/ml
phosphoascorbate for 2 weeks. Cells were treated with 10 nM PTH, 1 tM PGE or
PGF2 for 2 h. RNA was extracted and subjected to Northern blot analysis as described in
Materials and Methods.
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Figure llc Densitometry of osteocalcin expression normalized to actin for
MC3T3-E1 cells grown for 2 weeks in the presence or absence of phosphoascorbate (Asc).
This graph represents densitometric values for Figure 9b.

Figure 12a PTH, PGE and PGFa at 1 mM induce ICER MC3T3-E1 cells
cultured for three weeks in the presence or absence of ascorbic acid.
MC3T3-E1 cells were grown in the presence or absence of 50 gg/ml
phosphoascorbate for 3 weeks. Cells were treated with 10 nM PTH, 1 gM PGE2 or
PGF for 2 h. RNA was extracted and subjected to RT-PCR as described in Materials and
Methods.
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Figure 12b Osteocalcin expression is higher in ascorbate treated compared to
ascorbate untreated MC3T3-E1 cells cultured for three weeks.
MC3T3-E1 cells were grown in the presence or absence of 50 gg/ml
phosphoascorbate for 3 weeks. Cells were treated with 10 nM PTH, 1 gM PGEz or
PGF2a for 2 h. RNA was extracted and subjected to Northern blot analysis as described in
Materials and Methods.
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Figure 12c Densitometry of osteocalcin expression normalized to actin for
MC3T3-E1 cells grown in the presence or absence of phosphoascorbate (Asc) for 3 weeks.
This graph represents densitometric values for Figure 10b.
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